caroline robert: metric phase 3 study
Published 12 years ago • 195 plays • Length 6:23Download video MP4
Download video MP3
Similar videos
-
1:33
dr. robert on next steps following the phase iii combi-v study in melanoma
-
1:40
dr. robert on the phase iii combi-v study in braf-mutant melanoma
-
7:44
caroline robert, gustave roussy, villejuif, france:
-
7:34
melanoma - pr caroline robert
-
7:13
caroline robert: combi-v: dabrafenib and trametinib vs. vemurafenib 1st-line
-
5:40
immunotherapy and targeted therapies for melanoma
-
1:10
os results of a study evaluating dabrafenib and trametinib in melanoma
-
3:06
combi-d: phase 3 trial of dabrafenib plus trametinib in braf v600e/k-mutated melanoma
-
6:39
questions about sequencing in braf-mutant melanoma
-
1:52
dr. long on dabrafenib/trametinib in braf v600e-mutant melanoma
-
7:15
ecc 2015: new survival data from combi-v trial of combination of two targeted therapies in melanoma
-
2:21
updates on the secombit trial
-
1:19
dr. robert on potential of dabrafenib/trametinib in melanoma brain metastases
-
5:05
locoregional therapy for advanced melanoma
-
8:23
risk stratification for advanced melanoma
-
2:08
assessing textbook outcomes in borderline resectable stage iiib-d and iv melanoma
-
8:42
melanoma: mechanisms of resistance to therapy
-
2:19
dr. robert on 5-year analysis of dabrafenib/trametinib in braf v600-mutant melanoma
-
7:59
emerging agents and combinations for advanced melanoma